A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

NCT02285088 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects
Sickle Cell Disease

Interventions

DRUG: GBT440
DRUG: Placebo

Sponsor

Global Blood Therapeutics